Description:
This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety,
tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor
activity of H3B-8800 in subset of participants with Myelodysplastic Syndromes (MDS), Acute
Myeloid Leukemia (AML), or Chronic Myelomonocytic Leukemia (CMML). The study consists of two
parts, a dose escalation part (Part 1) exploring a multiple once daily (QD) schedules and an
expansion part (Part 2) exploring a twice daily (BID) schedule.
Title
- Brief Title: A Study of H3B-8800 in Participants With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
- Official Title: An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
Clinical Trial IDs
- ORG STUDY ID:
H3B-8800-G000-101
- SECONDARY ID:
2016-001792-70
- NCT ID:
NCT02841540
Conditions
- Leukemia, Myeloid, Acute
- Myelodysplastic Syndromes
- Leukemia, Myelomonocytic, Chronic
Interventions
Drug | Synonyms | Arms |
---|
H3B-8800 | | H3B-8800 (Dose Escalation and Expansion) |
Purpose
This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety,
tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor
activity of H3B-8800 in subset of participants with Myelodysplastic Syndromes (MDS), Acute
Myeloid Leukemia (AML), or Chronic Myelomonocytic Leukemia (CMML). The study consists of two
parts, a dose escalation part (Part 1) exploring a multiple once daily (QD) schedules and an
expansion part (Part 2) exploring a twice daily (BID) schedule.
Trial Arms
Name | Type | Description | Interventions |
---|
H3B-8800 (Dose Escalation and Expansion) | Experimental | H3B-8800 Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes/ Low Risk Myelodysplastic Syndromes/ Chronic Myelomonocytic Leukemia. | |
Eligibility Criteria
Inclusion Criteria:
1. Confirmed diagnosis of MDS, CMML, or AML. For the MDS expansion cohort, participants
must be lower-risk MDS, defined as low or intermediate-1 risk categorization per
International Prognostic Scoring System (IPSS) criteria that carries a missense SF3B1
mutation at a variant allele frequency of 5 percent (%) or higher.
2. The participant must meet the following criteria relevant to their specific diagnosis:
A. Participants with higher-risk MDS/CMML must be intolerant of hypomethylating agents
(HMAs) or not have responded to 4 treatment cycles of decitabine or 6 treatment cycles
of azacitidine, or must have progressed at any point after initiation of an HMA.
B. For dose escalation portion, participants with lower-risk MDS/CMML must be
transfusion-dependent for red blood cells or platelets (as determined by instructional
practices or local standard of care). For enrollment MDS expansion cohort, lower risk
MDS participants must be RBC transfusion dependent according to IWG 2006 criteria
(having received at least 4 units (U) of RBCs within 8 weeks for hemoglobin (Hb) of
less than (<) 9 gram per deciliter (g/dL) prior to first dose of H3B-8800).
Participants who are RBC transfusion-dependent must also have failed erythropoiesis
stimulating agents (ESA) (primary resistance or relapse after a response) or have
serum erythropoietin (EPO) levels greater than (>) 500 units per liter (U/L).
C. Participants with AML must either refuse or not be considered candidates for
intensive induction chemotherapy using consensus criteria for defining such
participants. Previously treated participants should have evidence of persistent or
recurrent AML in the peripheral blood and/or bone marrow that is refractory to, or has
relapsed from, their most recent prior line of treatment. For AML, participants must
have white blood cells (WBC) < 15*10^9/liter (L).
D. Participants with CMML must have been treated with at least one prior therapy
(hydroxyurea or a hypomethylating agent [HMA]).
3. Eastern Cooperative Oncology Group (ECOG) performance score of 0-2.
4. For expansion cohort- absolute neutrophil count (ANC) greater than or equal to (>=)
500/ microliter (mcL) (0.5*10^9/L).
5. For expansion cohort- platelet count >50,000/mcL (50*10^9/L).
6. Adequate baseline organ function.
Exclusion Criteria:
1. Diagnosis of a core binding factor leukemia (t(8;21), t(16;16) or inv(16)).
2. Participant is deemed candidate for hematopoietic stem cell transplants at the time of
enrollment (for AML participants only).
3. Family history of Leber Hereditary Optic Neuropathy, Autosomal Dominant Optic Atrophy,
Late-Onset Retinal Degeneration, Familial Dysautonomia or other hereditary
mitochondrial disease, unless the causative mutation(s) in the family have been
determined and the participant has tested negative for the mutation(s).
4. Known prior or current retinal or optic nerve disease (example, Retinitis Pigmentosa,
diabetic retinopathy, optic neuritis) based on screening ophthalmology assessment for
eligibility.
5. Corrected vision is worse than 20/40 unless due to cataracts.
6. Vitamin B12, folate or vitamin A deficiency. Rescreening following repletion therapy
is acceptable.
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Number of Participants with Dose-limiting Toxicities (DLTs) |
Time Frame: | Escalation Cycle 1 (28 days) |
Safety Issue: | |
Description: | |
Secondary Outcome Measures
Measure: | Area Under the Plasma Concentration-time Curve From Time 0 Through the Last Measurable Point (AUC0-t) |
Time Frame: | Part 1: Cycle 1 Days 1, 4,15: 0-24 hours post-dose; Part 2: Cycle 1 Days 1, 8: 0-24 hours post-dose, Cycle 1 Day 15: 0-4 hours post-dose, Cycle 2 Day 1, Cycle 3 Day 15 and Cycle 6 Day 15: 0.5 to 3 hours post dose (each cycle length=28 days) |
Safety Issue: | |
Description: | |
Measure: | Maximum Observed Plasma Concentration (Cmax) |
Time Frame: | Part 1: Cycle 1 Days 1, 4,15: 0-24 hours post-dose; Part 2: Cycle 1 Days 1, 8: 0-24 hours post-dose, Cycle 1 Day 15: 0-4 hours post-dose, Cycle 2 Day 1, Cycle 3 Day 15 and Cycle 6 Day 15: 0.5 to 3 hours post dose (each cycle length=28 days) |
Safety Issue: | |
Description: | |
Measure: | Time of Maximum Observed Plasma Concentration (Tmax) |
Time Frame: | Part 1: Cycle 1 Days 1, 4,15: 0-24 hours post-dose; Part 2: Cycle 1 Days 1, 8: 0-24 hours post-dose, Cycle 1 Day 15: 0-4 hours post-dose, Cycle 2 Day 1, Cycle 3 Day 15 and Cycle 6 Day 15: 0.5 to 3 hours post dose (each cycle length=28 days) |
Safety Issue: | |
Description: | |
Measure: | Objective Response Rate (ORR) |
Time Frame: | Up to approximately 50 months |
Safety Issue: | |
Description: | ORR will be defined as the percentage of participants achieving a best overall response of partial remission (PR) or complete remission (CR) (PR + CR), from first dose date until disease progression/recurrence. CR includes CR with incomplete blood count recovery (CRi) in AML participants and marrow CR in MDS participants and optimal marrow response in CMML participants. Response will be assessed by the Investigator and the independent central review based on 2006 International Working Group (IWG) response criteria for MDS, 2003 IWG criteria for AML, and the international consortium proposal of uniform response criteria for CMML published in 2015. |
Measure: | Duration of Response (DOR) |
Time Frame: | Up to approximately 50 months |
Safety Issue: | |
Description: | DOR will be defined as the time from the date of first documented CR/PR until the first documentation of confirmed relapse, or death, whichever comes first. |
Measure: | Number of Participants with Hematologic Improvement |
Time Frame: | Up to approximately 50 months |
Safety Issue: | |
Description: | |
Measure: | Number of Participants who Achieve Red Blood Cell (RBC) Transfusion Independence |
Time Frame: | Up to approximately 50 months |
Safety Issue: | |
Description: | |
Measure: | Part 2: The Number of Participants who Achieve Red Blood Cells (RBC) Transfusion Independence by Week 24 |
Time Frame: | Up to Week 24 |
Safety Issue: | |
Description: | |
Measure: | Time to Progression |
Time Frame: | Up to approximately 50 months |
Safety Issue: | |
Description: | |
Measure: | Overall Survival (OS) |
Time Frame: | Up to approximately 50 months |
Safety Issue: | |
Description: | Overall Survival is defined as the time from first dose date to the date of death from any cause. |
Measure: | Mortality Rate at 3 and 6 Months |
Time Frame: | Months 3 and 6 |
Safety Issue: | |
Description: | |
Details
Phase: | Phase 1 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | H3 Biomedicine Inc. |
Trial Keywords
- Myelodysplastic Syndromes
- Acute Myeloid Leukemia
- Chronic Myelomonocytic Leukemia
- H3B-8800
- Splicing Modulator
- CMML
- AML
- MDS
Last Updated
March 16, 2021